BDB-201 is under clinical development by Seven and Eight Biopharmaceuticals and currently in Phase III for Solid Tumor. According to GlobalData, Phase III drugs for Solid Tumor have a 64% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how BDB-201’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Orien X-010 (BDB-201) is under development for the treatment of acral melanoma, metastatic liver cancer and solid tumors. The drug candidate is administered through intratumor route. The drug candidate consists of a replicating recombinant attenuated herpes simplex virus type I (Type I Herpes Simplex Virus, HSV-1) oncolytic vectors isolated from Chinese Han population. The genotype of HSV-1 was deleted from the genome of OrienX-010 and the DNA fragment encoding human GM-CSF was inserted so that the product only replicates specifically in tumor cells.
Orien X-010 was also under development for the treatment of malignant solid tumors including liver cancer, pancreatic cancer and lung cancer.
For a complete picture of BDB-201’s drug-specific PTSR and LoA scores, buy the report here.